Tenaya Therapeutics (TNYA) Stock Forecast & Price Target

Compare

2,916 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TNYA Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Tenaya

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TNYA Stock 12 Month Forecast

Average Price Target

$9.57

▲(619.66% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Tenaya Therapeutics in the last 3 months. The average price target is $9.57 with a high forecast of $40.00 and a low forecast of $2.00. The average price target represents a 619.66% change from the last price of $1.33.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"$20","41":"$41","-1":"-$1","9.5":"$9.5","30.5":"$30.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.571428571428571,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,9.5,20,30.5,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.28,4.258461538461538,7.236923076923077,10.215384615384615,13.193846153846152,16.17230769230769,19.15076923076923,22.12923076923077,25.107692307692307,28.086153846153845,31.064615384615383,34.043076923076924,37.02153846153846,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.28,1.9178021978021977,2.5556043956043957,3.1934065934065936,3.831208791208791,4.4690109890109895,5.106813186813187,5.744615384615385,6.382417582417583,7.02021978021978,7.658021978021979,8.295824175824176,8.933626373626373,{"y":9.571428571428571,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.28,1.3353846153846154,1.3907692307692308,1.4461538461538461,1.5015384615384615,1.5569230769230769,1.6123076923076924,1.6676923076923078,1.7230769230769232,1.7784615384615385,1.833846153846154,1.8892307692307693,1.9446153846153846,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.94,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.51,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.68,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$40.00

Average Price Target$9.57

Lowest Price Target$2.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Cory Jubinville, PhD

LifeSci Capital

Buy

125.56%

Upside

Reiterated

12/20/25

Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Tenaya Therapeutics (TNYA)After updating our model, ... we reiterate our OUTPERFORM rating and our PT remains at $3/sh

Whitney Ijem

Canaccord Genuity

$6→$5

Buy

275.94%

Upside

Reiterated

12/19/25

Canaccord Genuity Keeps Their Buy Rating on Tenaya Therapeutics (TNYA)

Mani Foroohar

Leerink Partners

$3→$2

Buy

50.38%

Upside

Reiterated

12/15/25

Leerink Partners Reaffirms Their Buy Rating on Tenaya Therapeutics (TNYA)

Joseph Pantginis

H.C. Wainwright

$5→$3

Buy

125.56%

Upside

Reiterated

12/12/25

Promising Clinical Developments and FDA Approval Boost Tenaya Therapeutics' Buy Rating

Sami Corwin

William Blair

Buy

―

Reiterated

12/12/25

Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (NASDAQ: AUTL) and Tenaya Therapeutics (NASDAQ: TNYA)

Yasmeen Rahimi

Piper Sandler

$40

Buy

2907.52%

Upside

Reiterated

11/10/25

Tenaya Therapeutics (TNYA) Gets a Buy from Piper Sandler

Geulah Livshits

Chardan Capital

Buy

576.69%

Upside

Reiterated

11/10/25

Chardan Capital Reaffirms Their Buy Rating on Tenaya Therapeutics (TNYA)

Michael Ulz

Morgan Stanley

Buy

275.94%

Upside

Reiterated

11/10/25

Tenaya Therapeutics (TNYA) Receives a Buy from Morgan Stanley

Ritu Baral

TD Cowen

Buy

―

Reiterated

08/11/25

Buy Rating for Tenaya Therapeutics: Financial Stability and Promising Clinical Trial Results

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Cory Jubinville, PhD

LifeSci Capital

Buy

125.56%

Upside

Reiterated

12/20/25

Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Tenaya Therapeutics (TNYA)After updating our model, ... we reiterate our OUTPERFORM rating and our PT remains at $3/sh

Whitney Ijem

Canaccord Genuity

$6→$5

Buy

275.94%

Upside

Reiterated

12/19/25

Canaccord Genuity Keeps Their Buy Rating on Tenaya Therapeutics (TNYA)

Mani Foroohar

Leerink Partners

$3→$2

Buy

50.38%

Upside

Reiterated

12/15/25

Leerink Partners Reaffirms Their Buy Rating on Tenaya Therapeutics (TNYA)

Joseph Pantginis

H.C. Wainwright

$5→$3

Buy

125.56%

Upside

Reiterated

12/12/25

Promising Clinical Developments and FDA Approval Boost Tenaya Therapeutics' Buy Rating

Sami Corwin

William Blair

Buy

―

Reiterated

12/12/25

Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (NASDAQ: AUTL) and Tenaya Therapeutics (NASDAQ: TNYA)

Yasmeen Rahimi

Piper Sandler

$40

Buy

2907.52%

Upside

Reiterated

11/10/25

Tenaya Therapeutics (TNYA) Gets a Buy from Piper Sandler

Geulah Livshits

Chardan Capital

Buy

576.69%

Upside

Reiterated

11/10/25

Chardan Capital Reaffirms Their Buy Rating on Tenaya Therapeutics (TNYA)

Michael Ulz

Morgan Stanley

Buy

275.94%

Upside

Reiterated

11/10/25

Tenaya Therapeutics (TNYA) Receives a Buy from Morgan Stanley

Ritu Baral

TD Cowen

Buy

―

Reiterated

08/11/25

Buy Rating for Tenaya Therapeutics: Financial Stability and Promising Clinical Trial Results

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Tenaya Therapeutics

1 Month

xxx

Success Rate

7/16 ratings generated profit

Average Return

+12.91%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 43.75% of your transactions generating a profit, with an average return of +12.91% per trade.

3 Months

xxx

Success Rate

8/16 ratings generated profit

Average Return

+15.50%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +15.50% per trade.

1 Year

Cory Jubinville, PhDLifeSci Capital

Success Rate

7/16 ratings generated profit

Average Return

-16.62%

reiterated a buy rating 4 days ago

Copying Cory Jubinville, PhD's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of -16.62% per trade.

2 Years

xxx

Success Rate

5/16 ratings generated profit

Average Return

-29.29%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 31.25% of your transactions generating a profit, with an average return of -29.29% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TNYA Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TNYA has received 14 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TNYA average Analyst price target in the past 3 months is 9.57.

Each month's total comprises the sum of three months' worth of ratings.

TNYA Financial Forecast

TNYA Earnings Forecast

Next quarter’s earnings estimate for TNYA is -$0.12 with a range of -$0.17 to -$0.10. The previous quarter’s EPS was -$0.12. TNYA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year TNYA has Performed in-line its overall industry.

No data currently available

TNYA Sales Forecast

Next quarter’s sales forecast for TNYA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. TNYA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year TNYA has Performed in-line its overall industry.

TNYA Stock Forecast FAQ

What is TNYA’s average 12-month price target, according to analysts?

Based on analyst ratings, Tenaya Therapeutics’s 12-month average price target is 9.57.

What is TNYA’s upside potential, based on the analysts’ average price target?

Tenaya Therapeutics has 619.66% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TNYA a Buy, Sell or Hold?

Tenaya Therapeutics has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Tenaya Therapeutics’s price target?

The average price target for Tenaya Therapeutics is 9.57. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $2.00. The average price target represents 619.66% Increase from the current price of $1.33.

What do analysts say about Tenaya Therapeutics?

Tenaya Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of TNYA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Tenaya Therapeutics (TNYA) Stock Forecast & Price Target

TNYA Analyst Ratings

TNYA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Tenaya Therapeutics

TNYA Analyst Recommendation Trends

TNYA Financial Forecast

TNYA Earnings Forecast

TNYA Sales Forecast

TNYA Stock Forecast FAQ

Detailed List of Analyst Forecasts